Microsatellite Instability
18
1
4
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
3 terminated out of 18 trials
66.7%
-19.8% vs benchmark
6%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (18)
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
National Cohort of Colorectal Cancers With Microsatellite Instability
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Genetic Mutation in Epithelial Ovarian Cancer
Genetic Mutation in Recurrent Cervical Cancer
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact
MSI in Circulatory DNA of Endometrial Cancer
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer